Belatacept for Kidney Transplant

The Food and Drug Administration (FDA) has approved the drug Nulojix (belatacept) for the prevention of graft rejection after kidney transplants. Christian P. Larsen, Emory University, provides a nutshell explanation of how the drug works, how it might impact kidney transplant patients and what type of work went into the drug's development. The immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard drug cyclosporine.

"New Transplant Drug Belatacept: How It Works"
(1 min. 32 sec.)

"Transplant Drug Belatacept Shows Promise for Kidney Transplant"
(3 min. 33 sec.)

"New Transplant Drug Belatacept: Drug Research and Development"
(3 min. 53 sec.)